Cita APA

Cohen, A. D., Lee, H. C., Trudel, S., Abdallah, A., Callander, N., Libby, E., . . . Opalinska, J. (2020). MM-250: Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up. Clin Lymphoma Myeloma Leuk.

Chicago Style Citation

Cohen, Adam D., et al. "MM-250: Impact of Prolonged Dose Delays On Response With Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up." Clin Lymphoma Myeloma Leuk 2020.

Cita MLA

Cohen, Adam D., et al. "MM-250: Impact of Prolonged Dose Delays On Response With Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up." Clin Lymphoma Myeloma Leuk 2020.